ES2902549T3 - Inhibidor de tirosina cinasa y aplicación del mismo - Google Patents

Inhibidor de tirosina cinasa y aplicación del mismo Download PDF

Info

Publication number
ES2902549T3
ES2902549T3 ES17850066T ES17850066T ES2902549T3 ES 2902549 T3 ES2902549 T3 ES 2902549T3 ES 17850066 T ES17850066 T ES 17850066T ES 17850066 T ES17850066 T ES 17850066T ES 2902549 T3 ES2902549 T3 ES 2902549T3
Authority
ES
Spain
Prior art keywords
compound
mmol
distillation
added
dried
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17850066T
Other languages
English (en)
Spanish (es)
Inventor
Fang Sun
Youni Zhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LaNova Medicines Ltd
Original Assignee
LaNova Medicines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LaNova Medicines Ltd filed Critical LaNova Medicines Ltd
Application granted granted Critical
Publication of ES2902549T3 publication Critical patent/ES2902549T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES17850066T 2016-09-13 2017-06-22 Inhibidor de tirosina cinasa y aplicación del mismo Active ES2902549T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610822529.0A CN107235896B (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用
PCT/CN2017/089501 WO2018049861A1 (zh) 2016-09-13 2017-06-22 酪氨酸激酶抑制剂及其应用

Publications (1)

Publication Number Publication Date
ES2902549T3 true ES2902549T3 (es) 2022-03-28

Family

ID=59982910

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17850066T Active ES2902549T3 (es) 2016-09-13 2017-06-22 Inhibidor de tirosina cinasa y aplicación del mismo

Country Status (8)

Country Link
US (1) US10882853B2 (cg-RX-API-DMAC10.html)
EP (1) EP3511327B1 (cg-RX-API-DMAC10.html)
JP (1) JP7487921B2 (cg-RX-API-DMAC10.html)
KR (2) KR20190045354A (cg-RX-API-DMAC10.html)
CN (2) CN110437145A (cg-RX-API-DMAC10.html)
AU (1) AU2017325641B2 (cg-RX-API-DMAC10.html)
ES (1) ES2902549T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018049861A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3655406A1 (en) 2017-07-18 2020-05-27 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AU2019212800B2 (en) 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
CN112358469A (zh) * 2020-03-18 2021-02-12 北京康辰药业股份有限公司 血管生成抑制剂、其制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN105884695B (zh) * 2015-02-13 2019-02-26 山东轩竹医药科技有限公司 杂环衍生物类酪氨酸激酶抑制剂
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN105017163A (zh) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
CN105085416A (zh) * 2015-08-25 2015-11-25 佛山市赛维斯医药科技有限公司 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN105001168A (zh) * 2015-08-25 2015-10-28 佛山市赛维斯医药科技有限公司 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途

Also Published As

Publication number Publication date
KR102382039B1 (ko) 2022-04-01
US10882853B2 (en) 2021-01-05
EP3511327A4 (en) 2019-08-07
EP3511327B1 (en) 2021-10-27
WO2018049861A1 (zh) 2018-03-22
EP3511327A1 (en) 2019-07-17
KR20190045354A (ko) 2019-05-02
CN107235896B (zh) 2019-11-05
US20190248772A1 (en) 2019-08-15
JP7487921B2 (ja) 2024-05-21
CN110437145A (zh) 2019-11-12
CN107235896A (zh) 2017-10-10
AU2017325641A1 (en) 2019-04-11
AU2017325641B2 (en) 2021-08-26
KR20210143935A (ko) 2021-11-29
JP2019529435A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
CN107922417B (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
US10793543B2 (en) Selective C-KIT kinase inhibitor
KR102698366B1 (ko) 피라졸 피리미딘 유도체 및 이의 용도
ES2931537T3 (es) Pirrolopiridinas sustituidas como inhibidores de la quinasa similar al receptor de activina
BR112017003312B1 (pt) Compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
CN107698603B (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
AU2017325641B2 (en) Tyrosine kinase inhibitor and application thereof
KR20150074186A (ko) 헤테로아릴기 알킨 화합물 및 그 응용
CN103739616B (zh) 含噻唑基雷帕霉素类衍生物及其应用
CN117653636B (zh) 含稠合双环类化合物的抗癌药及该化合物的制药用途
WO2024140798A1 (zh) Menin抑制剂及其用途
WO2014090398A1 (en) Use of maleimide derivatives for preventing and treating leukemia
CN112047944A (zh) 一种选择性抑制激酶化合物及其用途
CN102688234B (zh) 吲哚酮衍生物作为rsk2抑制剂的合成与应用
WO2021115495A1 (zh) 一种小分子含硫杂环化合物
WO2015182625A1 (ja) Ras活性阻害薬及びその用途
EP4091670A1 (en) Crystal of imidazopyridinone compound or salt thereof
CN104045632A (zh) 抗肿瘤药物苯并二氢吡喃(噻喃)酰胺类化合物及其药学上可接受的盐及制备方法和应用
CN115244054B (zh) 次黄嘌呤化合物的晶体
CN109206435A (zh) 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
CN121991031A (zh) 一种(4-(6-甲氧基喹啉-4-羰基)-1-基)并-1,2-二酮类化合物及其制备方法和应用
HK40083277A (en) Crystal of imidazopyridinone compound or salt thereof
KR20240101433A (ko) Ron 억제제로서 신규한 화합물
EP4617269A1 (en) Novel compound as ron inhibitor
WO2024235106A1 (zh) 稠合吡咯环或稠合吡啶环的化合物